Dianthus Therapeutics Inc
DNTH
Market Cap$822.26M
Close$
$-4.47
118.1% downside
Current Fair Value
118.1% downsideOvervalued by 118.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $822.26 Million |
|---|---|
| Enterprise Value | $810.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.45 |
| Beta | 0 |
| Outstanding Shares | 34,227,038 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -16.91 |
|---|---|
| PEG | -21.23 |
| Price to Sales | - |
| Price to Book Ratio | 3.08 |
| Enterprise Value to Revenue | 302.32 |
| Enterprise Value to EBIT | -6.24 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...